The rise of GLP-1 drugs is revolutionizing healthcare, offering new hope in the fight against obesity and related conditions. These medications, initially developed for type 2 diabetes, have demonstrated significant weight loss benefits. This article explores how to invest in weight loss drug stocks, providing insights into how GLP-1 medications work, the key players in the market, and crucial considerations before investing.
GLP-1 Medications: A New Era in Weight Management
GLP-1 drugs, or glucagon-like peptide-1 receptor agonists, mimic the effects of the natural GLP-1 hormone. These drugs primarily target the pancreas and brain, regulating blood sugar and appetite, which leads to weight loss and improved blood sugar control. GLP-1 drugs stimulate the pancreas to release insulin in response to meal-related blood sugar increases, effectively lowering blood sugar levels after eating. They also reduce glucose production by the liver, further aiding blood sugar management.
Beyond diabetes and weight management, GLP-1s are showing promise in treating other conditions, including cardiovascular disease, sleep apnea, kidney disease, Alzheimer's, and Parkinson's. Research suggests these drugs may reduce the risk of heart attacks and strokes. They also hold the potential for managing sleep apnea and improving sleep quality by addressing the underlying obesity factor. Some researchers are exploring their potential in treating kidney disease, Alzheimer's, and Parkinson's.
Key Players in the GLP-1 Market
Novo Nordisk and Eli Lilly are the dominant forces in the GLP-1 market. However, other companies are emerging as potential contenders.
Novo Nordisk (NVO)
Novo Nordisk's GLP-1 portfolio includes Ozempic, Rybelsus, and Wegovy, all based on the peptide semaglutide. Ozempic and Rybelsus are used to treat diabetes, while Wegovy is FDA-approved for chronic weight management in obese patients. These medications share the same active ingredient, semaglutide, but target different conditions and use different routes of administration (injection versus oral).
Read also: The Ultimate Guide to Male Diet Supplements
Novo Nordisk is developing its next-generation GLP-1 candidates:
- CagriSema: A once-weekly injection being investigated as a potential treatment for adults with obesity and type 2 diabetes, with regulatory approval sought in the first quarter of 2026.
- Amycretin: A dual-action weight loss drug with both subcutaneous and oral formulations, showing promise in early trials.
Eli Lilly (LLY)
Eli Lilly manufactures several GLP-1 receptor agonists, including Mounjaro for type 2 diabetes and Zepbound for weight loss in adults. Both medications contain the same active ingredient, tirzepatide, and work by mimicking the actions of hormones in the gut that help regulate blood sugar and appetite.
Eli Lilly is also developing an oral GLP-1 medication, orforglipron, which has shown favorable results in phase 3 trials for weight loss and glycemic control in individuals with type 2 diabetes. Orforglipron is on track for FDA submission by the end of 2025.
Other Companies to Watch
Several other companies are vying for a piece of the obesity drug market, including:
- Amgen (AMGN): Developing an injectable weight loss treatment called maridebart cafraglutide or MariTide, which could be dosed monthly rather than weekly.
- Roche (RHHBY): Acquired Carmot in 2023, gaining access to three clinical-stage obesity drugs.
- Viking Therapeutics: Developing two formulations of its GLP-1 obesity drug VK2735, including a once-weekly injectable and an oral dose.
- Structure Therapeutics: Developing oral treatments for weight loss, including GSBR-1290 and ANPA-0073.
- AstraZeneca: Has reached an agreement with China’s Eccogene to license a daily weight loss pill known as ECC5004.
Factors to Consider Before Investing in GLP-1 Stocks
Investing in GLP-1 stocks involves several key considerations:
Read also: Meal replacement guide for women
- High Demand and Revenue Growth: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound have experienced immense popularity due to their weight loss effects, creating high demand and durable revenue growth streams for manufacturers.
- Market Competition: The GLP-1 market is attracting numerous companies, which could lead to opportunities for multiple winners.
- Valuation Concerns: The high demand for GLP-1 drugs has driven up some manufacturers' stock prices, raising concerns about overvaluation.
- Risk Tolerance: Investing in clinical-stage companies working on GLP-1 drugs is a higher-risk, higher-reward venture compared to investing in established pharmaceutical companies.
Investment Strategies
There are several approaches to investing in weight loss drug stocks:
- Individual Stocks: Investing in individual pharmaceutical companies involved in the GLP-1 market, such as Novo Nordisk, Eli Lilly, Amgen, or Roche.
- Emerging Biotechnology Firms: Investing in smaller biotechnology firms running clinical trials of novel approaches, such as Viking Therapeutics or Zealand Pharma.
- Exchange Traded Funds (ETFs): Investing in ETFs that hold shares of leaders in the GLP-1 industry, offering a diversified and less risky approach. One example is the Tema GLP-1, Obesity & Cardiometabolic ETF (HRTS).
- Supply Chain Enablers: Investing in companies that support the manufacturing and distribution of GLP-1 and weight loss drugs.
The Promise and Potential Risks of the Weight Loss Drug Market
The anti-obesity medication market has the potential to become a $500 billion market. This forecast is driven by the large number of individuals affected by obesity. By 2035, there will be 2 billion obese individuals, and up to 4 billion if one includes the overweight.
However, there are also risks to consider:
- Affordability: Coverage of these drugs requires payment upfront, with health and social benefits accruing over decades. Tighter coverage could mean slower growth.
- Valuation: The combined market capitalization of Novo Nordisk and Eli Lilly may already reflect optimistic estimates of the obesity market.
- Clinical Trial Failures: The failure rate in metabolic drugs from Phase I to approval is high, making it challenging to identify winners.
The Future of Weight Loss Drugs
The future of weight loss drugs will focus on addressing some of the major issues with GLP-1s, including:
- Supply and Oral Drugs: Developing oral non-peptide GLP-1 drugs to address the difficulty of manufacturing GLP-1s.
- Tolerability: Improving tolerability to reduce gastrointestinal side effects.
- Efficacy: Improving efficacy in terms of percentage weight loss or focusing on specific sub-niches, like liver diseases.
- Muscle Loss: Developing muscle-sparing drugs to pair with GLP-1s.
Read also: Chlorine Brand Comparison